Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Developmental and Epileptic Encephalopathy Market to Exhibit Growth at a Remarkable CAGR of 15.5% During the Forecast Period (2022-2032) | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

29 Nov, 2022, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

The dynamics of developmental and epileptic encephalopathy (DEE) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of emerging therapies during the forecast period

LAS VEGAS, Nov. 29, 2022 /PRNewswire/ -- DelveInsight's Developmental and Epileptic Encephalopathy Market Insights report includes a comprehensive understanding of current treatment practices, developmental and epileptic encephalopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Developmental and Epileptic Encephalopathy Market Report

  • As per DelveInsight analysis, the developmental and epileptic encephalopathy market size in the 7MM was approximately USD 1,371 million in 2021.
  • According to the assessment done by DelveInsight, the estimated total DEE diagnosed prevalent cases in the 7MM were approximately 235K in 2021. 
  • Leading developmental and epileptic encephalopathy companies such as Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Stoke Therapeutics, BioPharm Solutions, Praxis Precision Medicines, Epygenix, Longboard Pharmaceuticals, and others are developing novel DEE drugs that can be available in the developmental and epileptic encephalopathy market in the coming years.
  • The promising developmental and epileptic encephalopathy therapies in the pipeline include EPX-100, EPX-200, EPX-300, XEN 496, LP 352, STK-001, JBPOS0101, Soticlestat (OV935/TAK-935), Carisbamate, NBI-921352, NBI-827104, PRAX-562, and others.
  • The current therapeutic landscape of DEE in the United States is driven by current treatment practices which includes anti-epileptic drugs (AEDs), Epidiolex/Epidyolex (cannabidiol), Fintepla (Fenfluramine), Afinitor/Votubia (Everolimus), and others. 
  • In October 2022, after its acquisition by Pfizer, Biohaven Pharmaceuticals started a new course focusing on developing therapeutics that modulate the Kv7 Ion Channel for treating neurological and neuropsychiatric diseases.
  • In September 2022, after the US Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for the initial dose cohort. Following the approval of IND application Praxis Precision Medicines also announced plans to begin the PRAX-222 EMBRAVE clinical study for the treatment of pediatric patients with early-onset SCN2A DEE.
  • In August 2022, Jazz Pharmaceuticals announced the start of a new Phase III trial to study the efficacy and safety of Epidiolex (cannabidiol), also known as Epidyolex in Europe, in children and adolescents with Epilepsy and Myoclonic-Atonic Seizures (EMAS).

Discover which therapies are expected to grab the major developmental and epileptic encephalopathy market share @Developmental and Epileptic Encephalopathy Market Report

Developmental and Epileptic Encephalopathy Overview

Developmental and epileptic encephalopathy is a seizure disorder characterized by infantile spasms, a type of seizure. Spasms typically appear before the age of one. The prognosis for developmental and epileptic encephalopathy is bleak. This rare disease, typically described as progressive and incurable, is also associated with severe physical and cognitive disabilities and unexplained death.

The most common cause of epileptic encephalopathy in childhood is structural abnormalities, which can be congenital (such as cortical malformations) or acquired (such as hypoxic-ischemic after the EEG often evolves to atypical hypsarrhythmia, which is a transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.

Developmental and Epileptic Encephalopathy Epidemiology Segmentation

DelveInsight estimates that there were approximately 235K diagnosed prevalent cases of DEE in the 7MM in 2021.

Among the EU-4 countries, the diagnosed prevalent population of DEE was maximum in Germany in 2021.

The developmental and epileptic encephalopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Diagnosed Prevalent Population of DEE
  • Treated pool of DEE

Download the report to understand which factors are driving developmental and epileptic encephalopathy epidemiology trends @Developmental and Epileptic Encephalopathy Epidemiological Insights

Developmental and Epileptic Encephalopathy Treatment Market 

Some of the general principles and approach to pediatric epilepsy treatment can be found in the epileptic encephalopathy treatment. The best anti-epileptic treatment is chosen based on the type of epilepsy syndrome. Although anti-seizure medications are commonly used, some types of seizures are notoriously difficult to control. It is the primary method of controlling epileptic seizures and is almost always the first class of therapy medications. 

Some of the FDA-approved drugs used for DEE treatment include Epidiolex (Jazz Pharmaceuticals), Diacomit (Biocodex), Fintepla (Zogenix), Sabril (Lundbeck), Ztalmy (Marinus Pharmaceuticals), Afinitor Disperz/Votubia (Novartis), Sympazan (Aquestive Therapeutics), Trokendi XR (Supernus Pharmaceuticals), Onfi (Lundbeck), Banzel (Eisai Pharmaceuticals), Lamictal (GlaxoSmithKline), and others.

In some children, steroid therapy with adrenocorticotropic hormone (ACTH) or prednisone has been beneficial. When medications do not work well, a vagus nerve stimulator or the ketogenic diet may be considered in patients. Moreover, in children with seizures that begin in one area or involve only one side of the brain, epilepsy surgery may be an option. In these cases, a focal resection (removal of a single area) or a hemispherectomy (removal of the majority of one side of the brain) may be considered.

To know more about developmental and epileptic encephalopathy treatment options, visit @DEE Treatment Drugs 

Developmental and Epileptic Encephalopathy Pipeline Therapies and Key Companies

  • XEN496: Xenon Pharmaceuticals
  • Soticlestat: Takeda/Ovid Therapeutics
  • Carisbamate: SK Life Science
  • EPX-100 (Clemizole HCl): Epygenix
  • NBI-921352: Neurocrine Biosciences
  • STK-001: Stoke Therapeutics
  • NBI-827104: Neurocrine Biosciences
  • JBPOS0101: BioPharm Solutions
  • PRAX-562: Praxis Precision Medicines
  • EPX-200 (Lorcaserin): Epygenix
  • EPX-300: Epygenix
  • LP352: Longboard Pharmaceuticals

Learn more about the DEE FDA-approved drugs @Drugs for Developmental and Epileptic Encephalopathy Treatment 

Developmental and Epileptic Encephalopathy Market Dynamics

The dynamics of developmental and epileptic encephalopathy market is anticipated to change in the coming years. Ztalmy, the first licensed therapy for CDKL5 deficiency disorder, was recently approved in the United States, boosting the developmental and epileptic encephalopathy market growth. Moreover, the void left by a lack of licensed medications will be filled by further R&D advancement. In addition, Epidiolex and Fintepla continue to add new prescribers and expand their existing prescriber base due to their strong uptake.

Furthermore, the current competitive scenario for DEE is limited to a few therapies. Currently, the DEE market appears to be an unexplored area by pharmaceutical companies, and thus the companies have a significant opportunity to capture the potential developmental and epileptic encephalopathy market space. Emerging drugs with improved seizure control may positively impact the developmental and epileptic encephalopathy market landscape and patients' quality of life.

However, several factors are impeding the growth of the DEE market. Rare epileptic syndromes, such as LGS, Dravet Syndrome, and CDKL5 deficiency disorder, are extremely complex and heterogeneous diseases with multiple etiologies, posing several diagnostic challenges as the disease progresses.

Moreover, there is a lack of consensus on screening and treatment of comorbidities in rare epilepsies. The majority of DEE types have no approved therapies. Patients may be unable to afford expensive treatment options due to a low return on investment. Approved drugs such as Fintepla and Ztalmy are expensive. DEE is a group of conditions that can affect nearly every system in the body, and because the symptoms vary, the upcoming treatment options may not apply to a larger patient population. Thus, all these factors mentioned above altogether will hamper the developmental and epileptic encephalopathy market growth in the future.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Base Year

2021

Developmental and Epileptic Encephalopathy Market CAGR

15.5 %

Developmental and Epileptic Encephalopathy Market Size in 2021

USD 1,371 million

Key Developmental and Epileptic Encephalopathy Companies

Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Stoke Therapeutics, Neurocrine Biosciences, BioPharm Solutions, Praxis Precision Medicines, Epygenix, Longboard Pharmaceuticals, and others

Key Developmental and Epileptic Encephalopathy Therapies

XEN496, Soticlestat, Carisbamate, Carisbamate, EPX-100, NBI-921352, STK-001, NBI-827104, JBPOS0101, PRAX-562, EPX-200 (Lorcaserin), EPX-300, LP352, and others

Scope of the Developmental and Epileptic Encephalopathy Market Report

  • Therapeutic Assessment: Developmental and Epileptic Encephalopathy current marketed and emerging therapies
  • Developmental and Epileptic Encephalopathy Market Dynamics: Developmental and Epileptic Encephalopathy market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Developmental and Epileptic Encephalopathy Market Access and Reimbursement

Discover more about DEE drugs in development @Developmental and Epileptic Encephalopathy Clinical Trials

Table of Contents

1

Key Insights

2

Report Introduction

3

Executive Summary

4

Key Events

5

SWOT Analysis

6

Epidemiology and Market Methodology

7

Developmental and Epileptic Encephalopathy (DEE) Market Overview at a Glance

7.1

Market Share (%) Distribution by Therapies in 2021

7.2

Market Share (%) Distribution by Therapies in 2032

8

Disease Background and Overview

8.1

West Syndrome

8.2

Dravet Syndrome

8.3

Lennox–Gastaut Syndrome

8.4

Landau–Kleffner Syndrome (LKS) (Acquired Epileptic Aphasia)

8.5

Epilepsy with Continuous Spike-and-Waves during Slow-Wave Sleep

8.6

Doose Syndrome (myoclonic atonic epilepsy)

8.7

CDKL5 deficiency disorder (CDD)

8.8

Tuberous sclerosis complex (TSC)

8.9

Genetic Epilepsy

8.10

Biomarkers of epileptic encephalopathies

9

Treatment of DEE

9.1

Antiseizure medications

9.2

Steroid therapy

9.3

Other Therapies

9.4

Epilepsy surgery

9.5

Treatment Algorithm

10

Treatment Guidelines

11

Epidemiology and Patient Population of 7MM

11.1

Key Findings

11.2

Assumptions and Rationale

11.2.1

Dravet Syndrome

11.2.2

Lennox-Gastaut Syndrome

11.2.3

Ohtahara Syndrome

11.2.4

West Syndrome

11.2.5

Landau-Kleffner Syndrome

11.2.6

Tuberous Sclerosis Complex

11.2.7

CDKL5 deficiency disorder

11.2.8

Others

11.3

Diagnosed Prevalent Population of DEE in 7MM

11.4

United States

11.4.1

Diagnosed Prevalent Population of DEE in the United States

11.5

EU-4 and UK

11.5.1

Diagnosed Prevalence of DEE in the EU-4 and the UK

11.6

Japan

11.6.1

Diagnosed Prevalent Population of DEE in Japan

12

Marketed Drugs

12.1

Key Competitor

13

Emerging Drugs

13.1

Key Competitors

14

Developmental and Epileptic Encephalopathy (DEE): 7MM Market Analysis

14.1

Key Findings

14.2

Market Outlook

14.3

Key Market Forecast Assumptions

14.4

Attribute Analysis

14.5

Total Market Size of DEE in the 7MM

14.6

Market Size of DEE by Current and Emerging Therapies in the 7MM

14.7

United States Market Size

14.7.1

Total Market Size of DEE in the United States

14.7.2

Market Size of DEE by Current and Emerging Therapies in the United States

14.8

EU-4 and UK Market Size

14.8.1

Total Market size of DEE in the EU-4 and the UK

14.8.2

Market Size of DEE by Current and Emerging Therapies in EU-4 and the UK

14.9

Japan

14.9.1

Total Market size of DEE in Japan

14.9.2

Market Size of DEE by Current and Emerging Therapies in Japan

15

Market Drivers

16

Market Barriers

17

Unmet Needs

18

Market Access and Reimbursement

19

Appendix

19.1

Bibliography

19.2

Report Methodology

20

DelveInsight Capabilities

21

Disclaimer

22

About DelveInsight

Related Reports

Developmental and Epileptic Encephalopathy Epidemiology Forecast

Developmental and Epileptic Encephalopathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted developmental and epileptic encephalopathy epidemiology in the 7MM, i.e., the United States, EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Developmental and Epileptic Encephalopathy Pipeline

Developmental and Epileptic Encephalopathy Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key developmental and epileptic encephalopathy companies, including Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, among others.

Epilepsy Market

Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies, including Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, among others.

Refractory Epilepsy Pipeline

Refractory Epilepsy Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key refractory epilepsy companies, including Eisai, Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others.

Partial Epilepsy Pipeline

Partial Epilepsy Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key partial epilepsy companies, including GW Pharmaceuticals, Equilibre Biopharmaceuticals, among others.

Refractory Epilepsy Market

Refractory Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory epilepsy companies, including Eisai, Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others.

Other Trending Reports

Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market

Related Healthcare Blogs

Devices for Epilepsy Management

Developmental and Epileptic Encephalopathy Market Outlook

Epidiolex vs Fintepla: Fight in Rare Epilepsies

Related Healthcare Services

Healthcare Business Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services 

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

Modal title

Also from this source

Traumatic Brain Injury Market to Expand at a CAGR of 10.9% During the Study Period (2020-2034) Fueled by Advances in Treatment and Growing Healthcare Investments | DelveInsight

Traumatic Brain Injury Market to Expand at a CAGR of 10.9% During the Study Period (2020-2034) Fueled by Advances in Treatment and Growing Healthcare Investments | DelveInsight

DelveInsight's Traumatic Brain Injury Market Insights report includes a comprehensive understanding of current treatment practices, traumatic brain...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.